Answers are grounded in this paper and cite their sources.
Hepatitis C virus (HCV)-related cirrhosis is the leading indication for liver transplantation. Reinfection of the allograft with HCV is universal in all patients with pretransplantation viremia, and leads to histologically proven hepatitis in 50%-80% of these patients. Recent data have demonstrated significantly higher mortality among HCV-positive liver transplant recipients. For this subgroup of patients, retransplantation remains highly controversial. As current antiviral therapy is limited in efficacy and tolerability, an improved understanding of those patients at greatest risk of developing serious HCV-induced graft injury is necessary to optimize treatment.
No takes yet. Share an insight, caveat, or question.
Chan et al. (2003) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: